Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153281 | 0.72 | MEN1 (0.53) | OPRD1MEN1KMT2AOPRM1OPRK1 | |
| SCHEMBL4153276 | 0.72 | MEN1 (0.53) | OPRD1MEN1KMT2AOPRM1OPRK1 | |
| SCHEMBL21830993 | 0.72 | OPRD1 (0.39) | OPRD1OPRM1OPRK1OPRL1CYP2D6 | |
| SCHEMBL9842563 | 0.71 | OPRD1 (0.43) | OPRD1MEN1KMT2AOPRM1OPRK1 | |
| SCHEMBL4275684 | 0.70 | MEN1 (0.38) | OPRD1MEN1KMT2AOPRM1OPRK1 | |
| SCHEMBL4281028 | 0.69 | GRM7 (0.38) | MEN1KMT2AUSP2 | |
| SCHEMBL21831878 | 0.69 | OPRD1 (0.37) | OPRD1CYP2D6 | |
| SCHEMBL9530935 | 0.68 | MEN1 (0.51) | OPRD1MEN1KMT2AOPRM1OPRK1 | |
| SCHEMBL5623535 | 0.68 | MEN1 (0.51) | OPRD1MEN1KMT2AOPRM1OPRK1 | |
| SCHEMBL7317029 | 0.68 | MEN1 (0.51) | OPRD1MEN1KMT2AOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | OPRD1 229/4885MEN1 3119/4885KMT2A 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.